tirzepatide cv outcomes trial In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. , , Read the full SURPASS-CVOT Real-world efficacy of tirzepatide in
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10












:max_bytes(150000):strip_icc()/Health-GettyImages-2190382211-1cdb5299c31943bd92857173e09da74e.jpg)















